Cellular Biomedicine Group, Inc. is a clinical-stage biomedicine firm engaged in the development of immunotherapies for cancer and effective stem cell therapies for degenerative diseases
Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG’s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.
Our technology includes 2 major cell platforms:
- (i) Immune Cell therapy for treatment of a broad range of cancers using Cancer Vaccines, Chimeric Antigen Receptor T cell (“CAR-T”) and anti-PD-1 Technologies
- (ii) Human adipose-derived mesenchymal progenitor cells (“haMPC”) for treatment of joint and autoimmune diseases
Our primary research and manufacturing facilities are located in China. Our cellular platforms are based on technologies developed both in-house and obtained through acquisition, licensing and collaboration arrangements with other companies.